Value Advisors
Long/short equity

Long Syneron: Upside Supported By Competitor's IPO Valuation, Recent Peer Acquisition

Two recent events prove that Syneron-Candela (TICKER: ELOS), the leader in aesthetic medical devices, is trading at a deep discount to its universe. In fact, Syneron should trade not at its peer multiples but at a premium, for reasons detailed below. We initiate coverage on Syneron with a Strong Buy recommendation supported by 2 major transactions, and set a target price of $18. Syneron closed last night at $11.30 per share.

The first event occurred on December 6, 2013, when Lumenis filed for a $115 million IPO on NASDAQ. Lumenis is one of the main competitors of Syneron. The prospectus and the planned IPO clearly show how Syneron, the larger of the 2 companies, is trading at a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details